According to the National Comprehensive Cancer Network [3], for men with newly diagnosed PC, the most important factors in initial treatment selection include the anatomic extent of disease (tumor [T] stage), histologic grade (Gleason score or grade group), serum prostate-specific antigen (PSA) concentration, and age, as well as risk stratification schema for localized PC. The gene discussed is KLK3; the disease is neoplasm.